About Us

OncoTartis, Inc. is a private biotechnology company established in 2011. Company’s founding IP came from Prof. Andrei Gudkov’s laboratory at Roswell Park Cancer Institute (Buffalo, NY). OncoTartis develops a novel category of anti-cancer drugs directed against tissue-specific targets for a subset of cancers (breast, prostate, ovarian, melanoma and hematological malignancies). Its leading product OT-82 is a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor being developed to treat Acute Myeloid Leukemia (AML). Investigational New Drug application (IND) will be submitted to FDA in the forth quarter of 2017.

 

Read More

Technology

OncoTartis is exploring a proprietary drug discovery approach called “TARTIS” (TARTIS = TARgeting TISsue). TARTIS is designed to develop small molecules for treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organism (i.e., gender-associated tissues or melanocytes) or can be effectively replaced (hematopoietic system). TARTIS technology involves screening of chemical and/or shRNA libraries for identification of small molecules and shRNAs corresponding to specific genes, which are capable of selective killing of cells representing the tissue of choice.

Read More

Pipeline

An anti-AML candidate, OT-82, has a favorable set of structural, ADME and toxicological properties. A broad composition of matter patent application  was filed in December of 2013. OT-82 is an orally available NAMPT (NicotinAMide Phosphoribosyl Transferase) inhibitor. Found as a compound largely selective towards haematological malignancies, OT-82 is efficatious against broad range of leukemias and lymphomas.
OT-82 program has completed in vivo and ex vivo efficacy studies, developed CMC package and produced a kilo-scale batch for IND-enabling studies. Formal toxicology studies have been successfully completed in Russia and GLP tox studies will be completed in 4Q16. IND is expected to be filed in 1Q 2017.

 

Read More